gastroentrologists

BMS' Zeposia and AbbVie's Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn's Disease Markets, Spherix Reports
PR Newswire
Sun, 12/4/22 - 01:24 pm
Bristol Myers Squibb
AbbVie
Zeposia
Skyrizi
ulcerative colitis
Crohn's Disease
gastroentrologists